BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Clinical trial NCT02326844 · TERMINATED
Trial details
- NCT number
- NCT02326844
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-02
- Primary completion
- 2016-04-14
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.